Pat494
Legendary member
- Messages
- 14,614
- Likes
- 1,588
Go Pat Go!
Who would have believed it???
Pat on target to Gold - let's not jinxs it
Fingers crossed guys
1
12WBT
Last 5 for the year.
2045
2001
1998
2025
2029
Thanks
2045
2001
1998
2025
2029
Thanks
Atilla
Legendary member
- Messages
- 20,864
- Likes
- 4,040
Pat gets first gold of 2014! Wheheeeyyyyy! Well done Pat. :clap::clap::clap:
LexCorp gets silver and Postman Bronze. Good call considering there were were only 4 bulls in the pack.
..............................................................................Pat
................................LexCorp...................................................................................Postman
League Table here... sorted in Running Points order for the year. Column CE.
Gaffs way in the lead for top prize with Lex and Malaguti in pursuit. Malaguti's absence is unusual being a regular participant. Hope all is well.
LexCorp gets silver and Postman Bronze. Good call considering there were were only 4 bulls in the pack.
..............................................................................Pat
................................LexCorp...................................................................................Postman
League Table here... sorted in Running Points order for the year. Column CE.
Gaffs way in the lead for top prize with Lex and Malaguti in pursuit. Malaguti's absence is unusual being a regular participant. Hope all is well.
Atilla
Legendary member
- Messages
- 20,864
- Likes
- 4,040
2044 - Scientists warn that a global average temperature rise of 2°C – is the maximum safe limit, beyond which climate change will race out of control. Arctic becoming ice-free during summer. An even greater and more serious threat is emerging in the form of greenhouse gases from melting permafrost.
counter_violent
Legendary member
- Messages
- 12,672
- Likes
- 3,787
Too many people on the planet? Or shall we just overlook the bleedin obvious and just dismiss it as another inconvenient truth.
Pat494
Legendary member
- Messages
- 14,614
- Likes
- 1,588
And the answer to the planet over heating problem is ...................HYDROGEN
The bi products are water vapour when used as fuel. If planes had hydrogen burning engines the water vapour produced would make more clouds to reflect sunlight back into space. No shortage of water to make it too. Clean cars also.
:smart:
P
postman
You have to burn a heck of a lot of fossil fuels to extract Hydrogen, which just adds to the greenhouse effect.
http://en.wikipedia.org/wiki/Hydrogen_production
"Currently, the majority of hydrogen (∼95%) is produced from fossil fuels by steam reforming or partial oxidation of methane and coal gasification with only a small quantity by other routes such as biomass gasification or electrolysis of water."
2047.8 For me.
Who knows, just for once it might go down
Pat494
Legendary member
- Messages
- 14,614
- Likes
- 1,588
You have to burn a heck of a lot of fossil fuels to extract Hydrogen, which just adds to the greenhouse effect.
http://en.wikipedia.org/wiki/Hydrogen_production
"Currently, the majority of hydrogen (∼95%) is produced from fossil fuels by steam reforming or partial oxidation of methane and coal gasification with only a small quantity by other routes such as biomass gasification or electrolysis of water."
2047.8 For me.
Who knows, just for once it might go down
I read somewhere that The Orkneys produce it from electricity derived from wind power. Coal fired power stations are a definite no-no.
An electricity producing barrage could be built across the Bristol Channel.
M
malaguti
2016 for me please
Atilla
Legendary member
- Messages
- 20,864
- Likes
- 4,040
Hi Guys,
League table updated bulls to bears.
LexCorp is well bullish v ferocious bear Malaguti who is back after 6 weeks rest. We are missing Gaffs (hoping he hasn't been chewed up and spat out by the Black Friday rush :cheesy
Wishing you all good luck and festive cheers in this jolly month
League table updated bulls to bears.
LexCorp is well bullish v ferocious bear Malaguti who is back after 6 weeks rest. We are missing Gaffs (hoping he hasn't been chewed up and spat out by the Black Friday rush :cheesy
Wishing you all good luck and festive cheers in this jolly month
P
postman
Go and post where you belong http://www.zerohedge.com/
Are you a 'prepper' as well.
Gold is dead, silver is dead, long live the ever increasing number of dollars.
I think the combined debt is $12 Trillion now.
Atilla
Legendary member
- Messages
- 20,864
- Likes
- 4,040
Still have short bias on gold. This is a temporary pull back to possibly 1230 and may attempt a run to 1300s again if uncertainty creeps in. However, as equities are being supported by further QE in Japan and China's reductions in rates coupled with QE in EU I think dollar will continue to strengthen.
With strong dollar and cheap oil and equities supported with free cash only one direction left for gold and that's more downward pressure.
Silver obviously strongly correlated to gold but with impending slowdown in global growth and deflation not likely to see much of a jump.
As for oil, it's a question of how low can she go right now. Wait for significant sign of turn around. Don't see it at the mo. Russia is looking at dropping gas prices too and building a new pipeline into Europe. Suddenly we have excess energy.
We are on the cusp of a new era :clap:
Pat494
Legendary member
- Messages
- 14,614
- Likes
- 1,588
Got any spare dollars, pounds, rubles etc. then read this for 2015.
For months, I have been yelling from the rooftops that UK pharmaceutical giant GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) is going cheap, at least by its pricey standards.
Early last month it was still trading at just over 12 times earnings, well below the 15 or 16 times it normally stands at. I reckoned a company of this quality was unlikely to stay cheap for long, and the recovery has already begun. At 1501p, the share price is up 13% since its mid-October lows. Today, it trades at 13.6 times earnings.
So Glaxo is still relatively cheap. If I was buying just one stock for 2015 and beyond, here’s why it would be my choice.
GlaxoSmithKline plc (LON: GSK) is ending 2014 on a high and looks set fair for 2015, says Harvey Jones
The Glaxo share price was hammered for a reason. And it wasn’t just those unseemly Chinese bribery allegations (which may still draw crunching penalties from investigators in the US and UK).
Pharmaceutical and vaccination sales in the US have fallen sharply, down 10% in Q3 to $1.27bn, and the blame has largely fallen on Glaxo’s “patients first” programme, which was designed to sever the controversial link between bonuses and sales targets.
But there are questions over whether Glaxo’s sales teams have bought into the new system, which rewards staff for their scientific knowledge rather than their ability to drive prescription growth.
Worryingly, Glaxo is looking to expand the new incentive model across its global business next year, albeit with tweaks.
Glory Days
Glaxo has responded to sales slippage in the time-honoured way, with job cuts and a £1 billion restructuring programme, and is hoping two new lung treatments will compensate for falling US sales of inhaler Advair.
It has won some glory with “encouraging” early trials of its Ebola vaccine. And chief executive Sir Andrew Witty made waves with his announcement that Glaxo is looking to float the £15bn ViiV Healthcare businesses set up with Pfizer five years ago, with the proceeds likely to be passed to shareholders through extraordinary share buybacks.
Glaxo continues to post a strong performance in emerging markets, where populations are ageing and falling ill, as in the West. That’s now a key long-term reason to buy, especially as it seems to be forgiven in China.
Earnings per share are set to grow only a modest 1% in 2015, but that’s an improvement on this year’s 18% drop.
The very best reason to buy Glaxo is its 5.2% yield. Even if its troubles continue into 2015, you can re-invest that for long-term growth while the share price recovery continues.
For months, I have been yelling from the rooftops that UK pharmaceutical giant GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) is going cheap, at least by its pricey standards.
Early last month it was still trading at just over 12 times earnings, well below the 15 or 16 times it normally stands at. I reckoned a company of this quality was unlikely to stay cheap for long, and the recovery has already begun. At 1501p, the share price is up 13% since its mid-October lows. Today, it trades at 13.6 times earnings.
So Glaxo is still relatively cheap. If I was buying just one stock for 2015 and beyond, here’s why it would be my choice.
GlaxoSmithKline plc (LON: GSK) is ending 2014 on a high and looks set fair for 2015, says Harvey Jones
The Glaxo share price was hammered for a reason. And it wasn’t just those unseemly Chinese bribery allegations (which may still draw crunching penalties from investigators in the US and UK).
Pharmaceutical and vaccination sales in the US have fallen sharply, down 10% in Q3 to $1.27bn, and the blame has largely fallen on Glaxo’s “patients first” programme, which was designed to sever the controversial link between bonuses and sales targets.
But there are questions over whether Glaxo’s sales teams have bought into the new system, which rewards staff for their scientific knowledge rather than their ability to drive prescription growth.
Worryingly, Glaxo is looking to expand the new incentive model across its global business next year, albeit with tweaks.
Glory Days
Glaxo has responded to sales slippage in the time-honoured way, with job cuts and a £1 billion restructuring programme, and is hoping two new lung treatments will compensate for falling US sales of inhaler Advair.
It has won some glory with “encouraging” early trials of its Ebola vaccine. And chief executive Sir Andrew Witty made waves with his announcement that Glaxo is looking to float the £15bn ViiV Healthcare businesses set up with Pfizer five years ago, with the proceeds likely to be passed to shareholders through extraordinary share buybacks.
Glaxo continues to post a strong performance in emerging markets, where populations are ageing and falling ill, as in the West. That’s now a key long-term reason to buy, especially as it seems to be forgiven in China.
Earnings per share are set to grow only a modest 1% in 2015, but that’s an improvement on this year’s 18% drop.
The very best reason to buy Glaxo is its 5.2% yield. Even if its troubles continue into 2015, you can re-invest that for long-term growth while the share price recovery continues.
